ResearchHub | Open Science Community

Elani Streja

Author with expertise in Chronic Kidney Disease and Dialysis Treatment

Achievements

Cited Author

Open Access Advocate

Key Stats

Upvotes received:

Publications:

(67% Open Access)

Cited by:

521

h-index:

i10-index:

197

Reputation

Biology

< 1%

Chemistry

< 1%

Economics

< 1%

How is this calculated?

Publications

The Obesity Paradox and Mortality Associated With Surrogates of Body Size and Muscle Mass in Patients Receiving Hemodialysis

Kamyar Kalantar‐Zadeh et al.Oct 29, 2010

Paper

Save

Incremental Hemodialysis, Residual Kidney Function, and Mortality Risk in Incident Dialysis Patients: A Cohort Study

Yoshitsugu Obi et al.Feb 9, 2016

Paper

Save

Safety of SGLT2 inhibitors, DPP-4 inhibitors, and GLP-1 receptor agonists in US veterans with and without chronic kidney disease: a population-based study

Yoko Narasaki et al.Jun 18, 2024

We examined the real-world comparative safety of sodium-glucose cotransporter-2 inhibitors (SGLT2i) vs. other newer anti-glycemic medications (dipeptidyl peptidase-4 inhibitors [DPP4i], glucagon-like peptide-1 receptor agonists [GLP1a]) in patients with and without chronic kidney disease (CKD).

Pharmacology

Internal Medicine

Paper

Pharmacology

Save